Netscientific Share Discussion Threads

[blakieboy7] 16/5/2022 08:20

The price is moving up nicely on low volume so could easily get to a quid today imo

[peaky01] 16/5/2022 08:19

£1 today?

[blakieboy7] 16/5/2022 07:57

Also let's not forget PDSB phase 2 trial results due very soon

[senttothegallows] 16/5/2022 07:55

Simon Thompson points to asset value 1.27 from memory 19% rise in pdsb and ProAxis could be worth more than the current market cap. Interesting few days ahead imho

[blakieboy7] 16/5/2022 07:05

ProAxsis announces "impressive" results in performance evaluation of the in-licensed AstraZeneca COVID-19 antibody test -- Successful completion of evaluation of the AstraZeneca COVID-19 antibody test -- The assay showed exceptional levels of sensitivity and specificity of 100% and 99.3% respectively-- Successful development strengthens ProAxsis's expanding product range and international customer offering

[blakieboy7] 16/5/2022 07:05

Proaxis RNS out

[blakieboy7] 14/5/2022 13:10

Found it - htTps://www.investorschronicle.co.uk/ideas/2022/05/13/a-ben-graham-value-buy/

[blakieboy7] 14/5/2022 12:59

Do you have a link loaf?

[loafofbread] 14/5/2022 12:40

Nice tip in the IC last night.

[kingston78] 13/5/2022 16:25

The share price dipped a fraction this morning but then reversed positively a little. When I saw the share chart my interpretation was that it was the first sign of reversal (going up, breaking the downtrend). Now it has gone up by 2 p, which is more significant relatively. There were no surprises in the results of NSCI. Hopefully, one or more of its investments will hit the jackpot one day.

Investors knew the progress of PDSB before and after its recent results announcement. There was no change in brokers' consensus with a one year share price target of US$20, so I was puzzled as to why it had dropped so much. Now it has risen by 17% to US$4.50, which is still a long way from the one year target.

[blakieboy7] 13/5/2022 15:28

PDSB up 17%. Next week will hopefully propel the share price

[blakieboy7] 12/5/2022 18:21

I liked the comments relating to dividends

[loafofbread] 12/5/2022 18:02

Decent enough Investor Meet.

Looks like they have a fair amount of positive news to keep us interested going forward.

[blakieboy7] 12/5/2022 17:02

This material news explains why they directors haven't been able to buy shares

[blakieboy7] 12/5/2022 16:53

We're to expect news on Proaxis imminently- within a couple of working days I believe was said.

[kingston78] 12/5/2022 16:07

I will hold my shares in this company for the long term, hoping that one or more of its investments will bear fruit.

[k1ngkonggb] 12/5/2022 16:06

So back down to the 60's level again......one day Rodney!!!

[blakieboy7] 12/5/2022 11:21

Is anyone planning to listen in on the webinar later today?

[k1ngkonggb] 12/5/2022 09:03

Not exactly well received on these results. I realise that they're investing for the future so it looks like a 3-5 year realisation before we get back to some all time highs!

NSCI, prove me wrong otherwise!

[blakieboy7] 12/5/2022 07:47

htTps://www.proactiveinvestors.co.uk/companies/news/982058/netscientific-says-it-is-well-place-to-realise-optimal-shareholder-value-982058.html

[blakieboy7] 12/5/2022 07:32

From the results - (i) Options have been issued by ProAxsis Ltd and Glycotest, Inc. which if exercised would dilute the Company's shareholding by 5% and 66% respectively

[blakieboy7] 11/5/2022 16:12

Results day tomorrow

[loafofbread] 11/5/2022 12:30

11/05/2022 12:00pm
GlobeNewswire Inc.

PDS Biotechnology (NASDAQ:PDSB)
Intraday Stock Chart

Wednesday 11 May 2022

Click Here for more PDS Biotechnology Charts.
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, will discuss its financial results for the quarter ended March 31, 2022, and provide a business update on its conference call today.
“2022 is shaping up to be an incredibly productive year for PDS Biotech,” commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of the Company. “As we continue to make significant clinical progress on our lead oncology candidate, PDS0101, we’re looking ahead to presentations of preliminary data from our two most advanced Phase 2 clinical trials at this year’s ASCO meeting in early June. We believe ASCO’s selection of the preliminary data from both trials for presentation at the June meeting is a testament to the quality of work being done by our team and our partners, as well as the potential demonstrated by PDS0101 in treating advanced HPV-associated cancers. We look forward to sharing these efficacy and safety data in the near term. In addition, we continue to leverage our proprietary platforms to advance our pre-clinical pipeline into clinical studies, focused on a variety of cancer targets and infectious diseases. Lastly, due to our partnering model and our financial discipline, we finished the quarter with a strong cash balance which we project to fund our current operations into 2024.”

Recent Business Highlights:

Announced two abstracts accepted for poster presentation during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7 in Chicago:
The poster presentation of Abstract # 6041 will summarize updates to the preliminary efficacy and safety data from the PDS-sponsored VERSATILE-002 Phase 2 clinical trial, which is evaluating PDS0101 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.
The poster presentation of Abstract # 2518 will summarize updates from last year’s ASCO presentation to efficacy and survival data, as well as new findings from the ongoing National Cancer Institute (NCI)-led Triple Combination Phase 2 clinical trial. This trial is evaluating PDS0101 in combination with two investigational immune-modulating agents across the range of HPV16-positive advanced relapsed refractory cancers.
In April, received $1.2 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company’s participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program for State Fiscal Year 2021.
Announced that the NCI achieved the enrollment objective of 30 patients in the checkpoint inhibitor (CPI) refractory arm of the Triple Combination Phase 2 clinical trial for PDS0101.